MIRA Pharmaceuticals enrolls first subjects in Phase 1 trial of Ketamir-2 for neuropathic pain

MIRA PHARMACEUTICALS, INC.

Phase 1 trial of oral ketamine analog Ketamir-2 for neuropathic pain; 56 healthy volunteers in SAD/MAD cohorts.
Preclinical data showed superior efficacy vs. pregabalin and gabapentin in validated neuropathic pain models.
Study completion expected Q4 2025; Phase 2a in diabetic neuropathic pain to start by year-end 2025.
First human efficacy data anticipated in first half of 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.